nodes	percent_of_prediction	percent_of_DWPC	metapath
Mepenzolate—Diphenylpyraline—SLC6A3—attention deficit hyperactivity disorder	0.00871	0.566	CrCbGaD
Mepenzolate—CHRM2—forebrain—attention deficit hyperactivity disorder	0.00697	0.119	CbGeAlD
Mepenzolate—Benzatropine—SLC6A3—attention deficit hyperactivity disorder	0.00668	0.434	CrCbGaD
Mepenzolate—CHRM1—forebrain—attention deficit hyperactivity disorder	0.00634	0.109	CbGeAlD
Mepenzolate—CHRM2—cardiovascular system—attention deficit hyperactivity disorder	0.00589	0.101	CbGeAlD
Mepenzolate—CHRM3—forebrain—attention deficit hyperactivity disorder	0.00568	0.0973	CbGeAlD
Mepenzolate—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.00536	0.0919	CbGeAlD
Mepenzolate—CHRM3—Regulation of insulin secretion—ADRA2A—attention deficit hyperactivity disorder	0.00453	0.00489	CbGpPWpGaD
Mepenzolate—CHRM3—Integration of energy metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00428	0.00462	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00403	0.00435	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00399	0.00431	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00391	0.00423	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00388	0.00418	CbGpPWpGaD
Mepenzolate—CHRM2—nervous system—attention deficit hyperactivity disorder	0.00378	0.0648	CbGeAlD
Mepenzolate—CHRM3—Integration of energy metabolism—SNAP25—attention deficit hyperactivity disorder	0.00374	0.00404	CbGpPWpGaD
Mepenzolate—CHRM2—central nervous system—attention deficit hyperactivity disorder	0.00364	0.0624	CbGeAlD
Mepenzolate—CHRM3—Integration of energy metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00356	0.00385	CbGpPWpGaD
Mepenzolate—CHRM2—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.0035	0.00378	CbGpPWpGaD
Mepenzolate—CHRM1—nervous system—attention deficit hyperactivity disorder	0.00344	0.059	CbGeAlD
Mepenzolate—CHRM2—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00335	0.00362	CbGpPWpGaD
Mepenzolate—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.00332	0.0568	CbGeAlD
Mepenzolate—CHRM1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00329	0.00355	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00328	0.00354	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00325	0.0035	CbGpPWpGaD
Mepenzolate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00322	0.00348	CbGpPWpGaD
Mepenzolate—CHRM1—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00322	0.00348	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00321	0.00347	CbGpPWpGaD
Mepenzolate—CHRM3—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00321	0.00347	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0032	0.00345	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00319	0.00344	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00318	0.00343	CbGpPWpGaD
Mepenzolate—CHRM2—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00318	0.00343	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00316	0.00341	CbGpPWpGaD
Mepenzolate—CHRM3—nervous system—attention deficit hyperactivity disorder	0.00308	0.0528	CbGeAlD
Mepenzolate—CHRM3—central nervous system—attention deficit hyperactivity disorder	0.00297	0.0508	CbGeAlD
Mepenzolate—CHRM2—brain—attention deficit hyperactivity disorder	0.00289	0.0496	CbGeAlD
Mepenzolate—CHRM2—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00288	0.00311	CbGpPWpGaD
Mepenzolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00282	0.00304	CbGpPWpGaD
Mepenzolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00281	0.00303	CbGpPWpGaD
Mepenzolate—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00278	0.003	CbGpPWpGaD
Mepenzolate—CHRM1—Circadian rythm related genes—TPH2—attention deficit hyperactivity disorder	0.00277	0.00299	CbGpPWpGaD
Mepenzolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00276	0.00298	CbGpPWpGaD
Mepenzolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00275	0.00297	CbGpPWpGaD
Mepenzolate—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00272	0.00294	CbGpPWpGaD
Mepenzolate—CHRM2—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00268	0.00289	CbGpPWpGaD
Mepenzolate—CHRM2—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00268	0.00289	CbGpPWpGaD
Mepenzolate—CHRM1—brain—attention deficit hyperactivity disorder	0.00263	0.0451	CbGeAlD
Mepenzolate—CHRM3—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00255	0.00276	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00253	0.00273	CbGpPWpGaD
Mepenzolate—CHRM2—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00238	0.00256	CbGpPWpGaD
Mepenzolate—CHRM3—brain—attention deficit hyperactivity disorder	0.00236	0.0404	CbGeAlD
Mepenzolate—CHRM1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00223	0.00241	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00223	0.0024	CbGpPWpGaD
Mepenzolate—CHRM1—Circadian rythm related genes—SLC6A4—attention deficit hyperactivity disorder	0.00222	0.00239	CbGpPWpGaD
Mepenzolate—CHRM1—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.00222	0.00239	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.0022	0.00238	CbGpPWpGaD
Mepenzolate—CHRM1—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.00215	0.00232	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00215	0.00232	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00214	0.00231	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00212	0.00229	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0021	0.00227	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0021	0.00226	CbGpPWpGaD
Mepenzolate—CHRM1—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.00208	0.00225	CbGpPWpGaD
Mepenzolate—CHRM2—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.00208	0.00224	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00207	0.00224	CbGpPWpGaD
Mepenzolate—CHRM2—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00202	0.00218	CbGpPWpGaD
Mepenzolate—CHRM1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00195	0.00211	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00195	0.0021	CbGpPWpGaD
Mepenzolate—CHRM2—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00194	0.0021	CbGpPWpGaD
Mepenzolate—CHRM1—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.00194	0.0021	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00193	0.00208	CbGpPWpGaD
Mepenzolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00191	0.00207	CbGpPWpGaD
Mepenzolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00191	0.00206	CbGpPWpGaD
Mepenzolate—CHRM2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00189	0.00204	CbGpPWpGaD
Mepenzolate—CHRM2—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.00187	0.00202	CbGpPWpGaD
Mepenzolate—CHRM2—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.00184	0.00198	CbGpPWpGaD
Mepenzolate—CHRM2—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.00181	0.00196	CbGpPWpGaD
Mepenzolate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00181	0.00196	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00181	0.00195	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00181	0.00195	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.0018	0.00195	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00179	0.00193	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00178	0.00193	CbGpPWpGaD
Mepenzolate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00176	0.0019	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00175	0.00189	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00173	0.00187	CbGpPWpGaD
Mepenzolate—CHRM1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00173	0.00186	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00172	0.00186	CbGpPWpGaD
Mepenzolate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00171	0.00184	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00171	0.00184	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.0017	0.00184	CbGpPWpGaD
Mepenzolate—CHRM2—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00169	0.00183	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00168	0.00182	CbGpPWpGaD
Mepenzolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00167	0.00181	CbGpPWpGaD
Mepenzolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00167	0.0018	CbGpPWpGaD
Mepenzolate—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00165	0.00178	CbGpPWpGaD
Mepenzolate—CHRM2—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00164	0.00177	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00164	0.00177	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00164	0.00177	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00162	0.00175	CbGpPWpGaD
Mepenzolate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00159	0.00172	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00158	0.00171	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00157	0.00169	CbGpPWpGaD
Mepenzolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00155	0.00168	CbGpPWpGaD
Mepenzolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00155	0.00167	CbGpPWpGaD
Mepenzolate—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00153	0.00166	CbGpPWpGaD
Mepenzolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00151	0.00163	CbGpPWpGaD
Mepenzolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.0015	0.00162	CbGpPWpGaD
Mepenzolate—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00149	0.0016	CbGpPWpGaD
Mepenzolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00148	0.0016	CbGpPWpGaD
Mepenzolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00148	0.00159	CbGpPWpGaD
Mepenzolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00146	0.00158	CbGpPWpGaD
Mepenzolate—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00146	0.00158	CbGpPWpGaD
Mepenzolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00146	0.00157	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00146	0.00157	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00145	0.00157	CbGpPWpGaD
Mepenzolate—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00144	0.00156	CbGpPWpGaD
Mepenzolate—CHRM1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00144	0.00155	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00144	0.00155	CbGpPWpGaD
Mepenzolate—CHRM3—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00144	0.00155	CbGpPWpGaD
Mepenzolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00136	0.00147	CbGpPWpGaD
Mepenzolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00136	0.00147	CbGpPWpGaD
Mepenzolate—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00134	0.00145	CbGpPWpGaD
Mepenzolate—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00129	0.00139	CbGpPWpGaD
Mepenzolate—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00128	0.00139	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00127	0.00137	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00127	0.00137	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00126	0.00136	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00121	0.00131	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00121	0.0013	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.0012	0.00129	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00119	0.00128	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00118	0.00128	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00118	0.00128	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00118	0.00127	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00117	0.00127	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00117	0.00126	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00115	0.00124	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00114	0.00123	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00113	0.00122	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00113	0.00122	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00112	0.00121	CbGpPWpGaD
Mepenzolate—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00111	0.0012	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00111	0.0012	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00111	0.0012	CbGpPWpGaD
Mepenzolate—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00111	0.0012	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00111	0.0012	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.0011	0.00119	CbGpPWpGaD
Mepenzolate—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.0011	0.00119	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.0011	0.00119	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.0011	0.00118	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00109	0.00117	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00108	0.00116	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00108	0.00116	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00106	0.00115	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00104	0.00112	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00103	0.00112	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00102	0.00111	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00097	0.00105	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000967	0.00104	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000957	0.00103	CbGpPWpGaD
Mepenzolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000954	0.00103	CbGpPWpGaD
Mepenzolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000951	0.00103	CbGpPWpGaD
Mepenzolate—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000941	0.00102	CbGpPWpGaD
Mepenzolate—CHRM2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000871	0.00094	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000823	0.000889	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000821	0.000886	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000813	0.000877	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000775	0.000837	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000757	0.000817	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000755	0.000815	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000748	0.000807	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000747	0.000807	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000745	0.000805	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000738	0.000797	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000726	0.000784	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000724	0.000782	CbGpPWpGaD
Mepenzolate—CHRM1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.00072	0.000777	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00072	0.000777	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000717	0.000774	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000717	0.000774	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00071	0.000767	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000669	0.000722	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000667	0.00072	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00066	0.000713	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000653	0.000706	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000651	0.000703	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00065	0.000702	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000648	0.0007	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000648	0.0007	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000646	0.000697	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000645	0.000696	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000642	0.000693	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00064	0.000691	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000637	0.000688	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000637	0.000688	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000635	0.000686	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000635	0.000685	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000629	0.000679	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000629	0.000679	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000629	0.000679	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000627	0.000677	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000625	0.000675	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000623	0.000672	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000621	0.00067	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000617	0.000666	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000608	0.000656	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000606	0.000654	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.0006	0.000647	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000588	0.000635	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000586	0.000633	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000586	0.000633	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000584	0.000631	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000581	0.000627	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000578	0.000624	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000578	0.000624	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000576	0.000622	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000571	0.000617	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000571	0.000616	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000569	0.000615	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000564	0.000609	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000535	0.000578	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000535	0.000578	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000532	0.000574	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00053	0.000573	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000526	0.000568	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000525	0.000567	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000489	0.000528	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000442	0.000477	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00044	0.000475	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000436	0.000471	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000428	0.000462	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00041	0.000443	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000409	0.000442	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000407	0.00044	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000405	0.000437	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000386	0.000417	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000385	0.000415	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000381	0.000411	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000373	0.000402	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000371	0.000401	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000368	0.000397	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000359	0.000387	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000358	0.000386	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000354	0.000382	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000348	0.000375	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000346	0.000374	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000343	0.00037	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000342	0.000369	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000341	0.000368	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000337	0.000364	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000337	0.000364	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000336	0.000363	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000333	0.00036	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—COMT—attention deficit hyperactivity disorder	0.000324	0.00035	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000322	0.000348	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000314	0.000339	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000313	0.000338	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00031	0.000335	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00022	0.000238	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000219	0.000237	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000217	0.000235	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—EP300—attention deficit hyperactivity disorder	0.000139	0.00015	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000117	0.000126	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000116	0.000126	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000115	0.000124	CbGpPWpGaD
